163 related articles for article (PubMed ID: 10022444)
21. The effects of pathophysiological increments in brain natriuretic peptide in left ventricular systolic dysfunction.
Lainchbury JG; Richards AM; Nicholls MG; Hunt PJ; Ikram H; Espiner EA; Yandle TG; Begg E
Hypertension; 1997 Sep; 30(3 Pt 1):398-404. PubMed ID: 9314423
[TBL] [Abstract][Full Text] [Related]
22. Different compartmentation of responses to brain natriuretic peptide and C-type natriuretic peptide in failing rat ventricle.
Moltzau LR; Aronsen JM; Meier S; Skogestad J; Ørstavik Ø; Lothe GB; Sjaastad I; Skomedal T; Osnes JB; Levy FO; Qvigstad E
J Pharmacol Exp Ther; 2014 Sep; 350(3):681-90. PubMed ID: 25022512
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of the natriuretic effects of neutral endopeptidase inhibition in Dahl salt-sensitive and salt-resistant rats.
Hirata Y; Suzuki E; Hayakawa H; Matsuoka H; Sugimoto T; Kangawa K; Matsuo H
J Cardiovasc Pharmacol; 1994 Feb; 23(2):283-90. PubMed ID: 7511759
[TBL] [Abstract][Full Text] [Related]
24. Renal, endocrine, and hemodynamic interactions of atrial and brain natriuretic peptides in normal men.
Florkowski CM; Richards AM; Espiner EA; Yandle TG; Frampton C
Am J Physiol; 1994 Apr; 266(4 Pt 2):R1244-50. PubMed ID: 8184968
[TBL] [Abstract][Full Text] [Related]
25. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA
J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
[TBL] [Abstract][Full Text] [Related]
26. Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure.
Chen HH; Lainchbury JG; Matsuda Y; Harty GJ; Burnett JC
Hypertension; 2001 Aug; 38(2):187-91. PubMed ID: 11509474
[TBL] [Abstract][Full Text] [Related]
27. Potentiation of natriuretic peptides by neutral endopeptidase inhibitors.
Seymour AA; Abboa-Offei BE; Smith PL; Mathers PD; Asaad MM; Rogers WL
Clin Exp Pharmacol Physiol; 1995 Jan; 22(1):63-9. PubMed ID: 7768036
[TBL] [Abstract][Full Text] [Related]
28. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats.
Gonzalez Vera W; Fournié-Zaluski MC; Pham I; Laboulandine I; Roques BP; Michel JB
J Pharmacol Exp Ther; 1995 Jan; 272(1):343-51. PubMed ID: 7815350
[TBL] [Abstract][Full Text] [Related]
29. Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure.
Martin FL; Stevens TL; Cataliotti A; Schirger JA; Borgeson DD; Redfield MM; Luchner A; Burnett JC
Kidney Int; 2005 May; 67(5):1723-30. PubMed ID: 15840018
[TBL] [Abstract][Full Text] [Related]
30. Potentiation of brain natriuretic peptides by SQ 28,603, an inhibitor of neutral endopeptidase 3.4.24.11, in monkeys and rats.
Seymour AA; Asaad MM; Abboa-Offei BE; Rovnyak PL; Fennell S; Rogers WL
J Pharmacol Exp Ther; 1992 Jul; 262(1):60-70. PubMed ID: 1385630
[TBL] [Abstract][Full Text] [Related]
31. Hemodynamic and humoral effects of chronic treatment with the neutral endopeptidase inhibitor SCH 42495 in spontaneously hypertensive rats.
Sala C; Monopoli A; Casati C; Ardeleani G; Ongini E; Zanchetti A; Morganti A
J Cardiovasc Pharmacol; 1994 May; 23(5):703-8. PubMed ID: 7521451
[TBL] [Abstract][Full Text] [Related]
32. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension.
Pham I; Gonzalez W; el Amrani AI; Fournié-Zaluski MC; Philippe M; Laboulandine I; Roques BP; Michel JB
J Pharmacol Exp Ther; 1993 Jun; 265(3):1339-47. PubMed ID: 8389863
[TBL] [Abstract][Full Text] [Related]
33. Bioactivity and metabolism of C-type natriuretic peptide in normal man.
Hunt PJ; Richards AM; Espiner EA; Nicholls MG; Yandle TG
J Clin Endocrinol Metab; 1994 Jun; 78(6):1428-35. PubMed ID: 8200946
[TBL] [Abstract][Full Text] [Related]
34. [Functional compartmentation of the endocrine action of cardiac natriuretic peptides].
Haloui M; Arnal JF; Pham I; Gonzalez W; Lyoussi B; Michel JB
Ann Endocrinol (Paris); 2000 Feb; 61(1):32-40. PubMed ID: 10790590
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms underlying the augmented responses of deoxycorticosterone acetate-salt hypertensive rats to neutral endopeptidase inhibitors.
Hirata Y; Suzuki Y; Suzuki E; Hayakawa H; Kimura K; Goto A; Omata M; Minamino N; Kangawa K; Matsuo H
J Hypertens; 1994 Apr; 12(4):367-74. PubMed ID: 8064160
[TBL] [Abstract][Full Text] [Related]
36. Long-term treatment with neutral endopeptidase inhibitor improves cardiac function and reduces natriuretic peptides in rats with chronic heart failure.
Maki T; Nasa Y; Yamaguchi F; Yoshida H; Mori M; Takada T; Horikawa E; Okano K; Takeo S
Cardiovasc Res; 2001 Aug; 51(3):608-17. PubMed ID: 11476752
[TBL] [Abstract][Full Text] [Related]
37. Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep.
Charles CJ; Espiner EA; Nicholls MG; Richards AM; Yandle TG; Protter A; Kosoglou T
Am J Physiol; 1996 Aug; 271(2 Pt 2):R373-80. PubMed ID: 8770137
[TBL] [Abstract][Full Text] [Related]
38. Biochemical analysis of neutral endopeptidase activity reveals independent catabolism of atrial and brain natriuretic peptide.
Walther T; Stepan H; Pankow K; Becker M; Schultheiss HP; Siems WE
Biol Chem; 2004 Feb; 385(2):179-84. PubMed ID: 15101560
[TBL] [Abstract][Full Text] [Related]
39. Interaction of a neutral endopeptidase inhibitor with an ANP-C receptor ligand in anesthetized dogs.
Wegner M; Stasch JP; Hirth-Dietrich C; Dressel J; Voges KP; Kazda S
Clin Exp Hypertens; 1995 Aug; 17(6):861-76. PubMed ID: 7581258
[TBL] [Abstract][Full Text] [Related]
40. Antihypertrophic effects of combined inhibition of the renin-angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure.
Birner C; Ulucan C; Bratfisch M; Götz T; Dietl A; Schweda F; Riegger GA; Luchner A
Naunyn Schmiedebergs Arch Pharmacol; 2012 Nov; 385(11):1117-25. PubMed ID: 22895639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
